Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lobaplatin + paclitaxel versus carboplatin + paclitaxel as neoadjuvant chemotherapy for stage II/III triple-negative breast cancer
ChiCTR1800016272Phase 4Recruiting
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- May 2018
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of lobaplatin, carboplatin and paclitaxel in triple-negative breast cancer (TNBC) (2 arms), sponsored by The Fourth Hospital of Hebei Medical University. Primary endpoints: Pathological complete response and Safety. Started May 2018; status: recruiting.
02
Drugs
lobaplatincarboplatinpaclitaxel
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on ChiCTR1800016272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800016272.